Celgene (CELG) Stock Gains on 10-Year $1 Billion Drug Development Deal With Juno

NEW YORK (TheStreet) -- Celgene (CELG) shares are up 0.63% to $115.65 in early market trading after the company entered into a 10 year $1 billion drug development deal with Juno Therapeutics (JUNO) today.

Under the terms of the deal Celgene will pay Juno $150 million in cash and acquire 9.1 million shares of Juno at $93 per share.

Celgene in return has the right to acquire up to a 30% stake in Juno while also garnering a nomination to Juno's board.

The initial focus of the drug development deal will be on a portfolio of Car-T and T-cell receptor technologies.

Separately, Juno also said that it received approval to launch Phase I trials of its non-Hodgkin lymphoma treatment.

Juno shares are up 0.73% to $115.64.

TheStreet's Jim Cramer, portfolio manager of the Action Alerts PLUS charitable trust, believes that Celgene paid a lot to have access to Juno's immunotherapy portfolio. Though he acknowledges that the sector is the future of the cancer treatment industry:

"Celgene paid a fortune for this stake making me wonder who else wanted it. That said immunotherapy is the future of the fight against cancer and I think Celgene wanted intel on how it works. High ante to find out," said Cramer.

TheStreet Ratings team rates CELGENE CORP as a Buy with a ratings score of B+. TheStreet Ratings Team has this to say about their recommendation:

If you liked this article you might like

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Apple Is the Tom Brady of Stocks: Cramer's 'Mad Money' Recap (Thursday 8/31/17)

Cramer: Fantasy Shmantasy -- Let's Get Real With These Stock Picks